CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors.
Rodriguez Rivera I, Hafez N, Tolcher A, LoRusso P, Wilks S, Tripathy D, Gara M, Pearson P, DeCillis A, Meric-Bernstam F. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. Journal Of Clinical Oncology 2023, 41: 3087-3087. DOI: 10.1200/jco.2023.41.16_suppl.3087.Peer-Reviewed Original ResearchTreatment-related AEsOvarian cancerBreast cancerFrequent treatment-related AEsHER2-negative breast cancerPlatinum-resistant ovarian cancerDaily x 3Daily x 5Hormone receptor positiveSingle-agent antitumor activityMetastatic solid tumorsPhase 1 trialAnti-drug antibodiesNegative breast cancerAnti-tumor activityAntibody-drug conjugatesFebrile neutropeniaRECIST v1.1WBC decreaseExpansion cohortFIH studiesPlasma PKTumor cell membranesHuman studiesSolid tumorsTargeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria
Xie X, Yang Y, Wang Q, Liu H, Fang X, Li C, Jiang Y, Wang S, Zhao H, Miao J, Ding S, Liu X, Yao X, Yang W, Jiang J, Shao Z, Jin G, Bian X. Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research 2023, 33: 215-228. PMID: 36627348, PMCID: PMC9977947, DOI: 10.1038/s41422-022-00766-z.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsPD-L1Combination therapyTherapeutic responsePD-1/PD-L1 signalingShorter progression-free survivalBreast cancer benefitProgression-free survivalPD-L1 signalingCheckpoint inhibitorsNab-paclitaxelCancer benefitImmunotherapy cohortImmune microenvironmentPreclinical resultsTumor cell membranesTumor samplesPaclitaxelHigh expressionPromising targetPatientsTherapyTumorsResistant factorATAD3A expression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply